DOSAGE INDEX / SINGLE
PE-22-28
Research, reported schedules and supply planning.
Examine PE-22-28 channel experiments and mouse findings without converting preclinical activity or analog results into proven human depression treatment.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 50–200 micrograms per day
- Frequency
- Once daily
- Cycle / observation period
- 12–16 weeks; source names 8 weeks as a minimum
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- PE-22-28 is a seven-amino-acid peptide examined in a 2017 study of shortened spadin analogs. Researchers tested ion-channel activity in cells and antidepressant-like responses in mice. The paper provides a preclinical rationale; it does not establish a treatment for depression in people. [1]
- In mice, the research included forced-swim and novelty-suppressed-feeding outcomes. The authors reported reduced immobility and shorter feeding latency in relevant experiments. They also examined neuronal markers and a series of analogs, with some stronger findings belonging to a modified analog rather than unmodified PE-22-28. [1]
- The original article reports longer experimental action for PE-22-28 and its analog series than for spadin. That result is not a measured human elimination half-life or a validated human administration interval. [1]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 10 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- Original study
- PLoS Biology (2010)Further reading · Listed in reference bibliography.
- Neuropharmacology (2012)Further reading · Listed in reference bibliography.
- Frontiers in Pharmacology (2017)Further reading · Listed in reference bibliography.
- Neuropharmacology (2019)Further reading · Listed in reference bibliography.
- Pharmacological Research (2021)Further reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- Centers for Disease Control and PreventionGeneral guidance · Listed in reference bibliography.
- International Journal of Molecular Sciences (2022)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.